Contact Us: 01282 426380
KM Financial Solutions | GSK’s new R&D head bets on genetics with $300 mln 23andMe deal
23556
post-template-default,single,single-post,postid-23556,single-format-standard,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-child-theme-ver-1.0.0,qode-theme-ver-11.2,qode-theme-bridge,wpb-js-composer js-comp-ver-5.2.1,vc_responsive
 

GSK’s new R&D head bets on genetics with $300 mln 23andMe deal

24 Jul GSK’s new R&D head bets on genetics with $300 mln 23andMe deal

Posted at 10:04h in News by
0 Likes
GlaxoSmithKline’s new
research boss aims to turbo-charge the British group’s drug
discovery engine with a $300 million bet on genetics by buying a
stake in the Silicon Valley gene testing company 23andMe.

No Comments

Sorry, the comment form is closed at this time.